Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 and ED90 of esketamine for catheter-related bladder discomfort in PACU
ChiCTR2500108178Phase 4Not yet recruiting
- Sponsor
- Peking University Shenzhen Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of esketamine in cystitis, sponsored by Peking University Shenzhen Hospital. Primary endpoint: Median effective dose (ED50) of esketamine. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
cystitis
Beyond the preview
Go deeper on ChiCTR2500108178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108178.